Ambalal Sarabhai Enterprises Share Price

Ambalal Sarabhai Enterprises Ltd., incorporated on June 5, 1978, houses a range of companies across multidimensional businesses. Each subsidiary is a distinct entity contributing its unique expertise and capabilities. It is one of the oldest pharmaceutical health care companies in India, and today through its group companies it manufactures and markets pharmaceutical, molecular diagnostics, and electronics products in India and internationally. ASEs strength is to lead with cutting edge technology by creating strategic technology tieups and collaborative partnerships through our broad national and international networksThe Company produces a range of bulk drugs, pharmaceutical preparations and electronic instruments. It operates in two segments, pharmaceuticals and electronics. Pharmaceuticals segment is engaged in manufacture of drugs and formulations. Electronics segment is engaged in manufacture of electronics instruments and services. In the year 1994, the company entered into a technical collaboration with Biobras, Brazil, to manufacture highly purified insulin injections. During the year 199798, the company formed a joint venture company, namely Sarabhai Piramal Pharmaceuticals Ltd with Piramal Enterprises Ltd for marketing of certain products under trademarks being used by the company. During the year 199899, the company signed agreement with B V Chiron, Netherlands for introducing their anticancer drugs in India.During the year 19992000, the company entered into an MoU for marketing of products of Oncology products of Chiron Corporation, USA. The Product Division essentially comprising of Sarabai Chemicals Products was transferred to the joint venture company, Sarabhai Piramal Pharmaceuticals Ltd. In September 2008, the company acquired the manufacturing and marketing company, namely Suvik Hitek Pvt. Ltd. The Ethical Division relaunched the products of Suvik and Sarabhai Chemicals in market. Also, the company acquired Systronics (India) Pvt Ltd. During the year 200809, the Oncology Division launched two new products viz. Fludagem Xtinib. Also, the company promoted a company viz. Vovanties Laboratories Pvt Ltd, a pharmaceutical specialist with a vision to establish a state of the art manufacturing facility specializing in Novel Effervescent Drug Delivery System. During the year 201011, the Company had transferred and assigned as going concern, the business undertaking of Sarabhai Chemicals Bulk Drug Division to Synbiotics Ltd and Electronics Division comprising of Systronics, Teleradand SERC to Systronics (India) Ltd with effect from October 01, 2010.Sarabhai M Chemicals Ltd, a wholly owned subsidiary company started its Vitamin C coated products manufacturing since August 2019.In June 2023, Asence Pharma Pvt., Ltd. a subsidiary of the Company commenced its new oncology and synthetic API plant at Ranoli, Vadodara.

Ambalal Sarabhai Enterprises reported a Q2 FY2025–2026 revenue of ₹40.34 crore, up 12.8% YoY, with net profit decreased -48.9% to ₹8.24 crore. For the full year FY2025–2026, revenue reached ₹207.57 crore and profit touched at ₹4.29 crore. As of Jun '25, Ambalal Sarabhai Enterprises’s market capitalisation stood at ₹258.71 crores. Shareholding as of Jun '25 shows promoters holding 31.4%, with FIIs at 0.4%, DIIs at %, and public at %.

As of 19 Aug, 2025, Ambalal Sarabhai Enterprises share price is ₹33.8. The stock opened at ₹33.6 and had closed at ₹33.4 the previous day. During today’s trading session, Ambalal Sarabhai Enterprises share price moved between ₹33.00 and ₹34.00, with an average price for the day of ₹33.50. Over the last 52 weeks, the stock has recorded a low of ₹30.00 and a high of ₹69.75. In terms of performance, Ambalal Sarabhai Enterprises share price has declined by 21.8% over the past six months and has declined by 45.66% over the last year.